Humacyte announced $2 million in total revenue for 2025, driven by sales of its bioengineered vessel product Symvess and research collaborations. The company is expanding Symvess commercialization internationally, including a $1.475 million purchase commitment from Saudi Arabia and a Marketing Authorization Application submitted in Israel. A major milestone is expected in Q2 2026 with interim results from the V012 Phase 3 study of their acellular tissue engineered vessel (ATEV) for hemodialysis access, moving toward a planned BLA filing later in 2026. Humacyte also progressed its coronary tissue engineered vessel (CTEV) toward human trials, supporting its pipeline growth and future commercial opportunities.
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
